Market

Biotech Sector Volatility Hits Nurix and Karyopharm Share Prices
Research & Development Biotech Sector Volatility Hits Nurix and Karyopharm Share Prices

The recent bankruptcy filing of Karyopharm Therapeutics includes a restructuring support agreement and a $55 million debtor-in-possession financing package to maintain clinical operations. This development serves as a sobering reminder of the razor-thin margins for error that currently define the

Cencora Launches Gene Therapy Service Amid Biotech Shifts
Research & Development Cencora Launches Gene Therapy Service Amid Biotech Shifts

The Neonatal Fc receptor has emerged as a high-value target in immunology because it plays a critical role in recycling the antibodies that sustain autoimmune activity. This shift toward complex, target-specific medicine is forcing the global pharmaceutical infrastructure to evolve beyond simple

EU Pharma Reform Changes the Investment Case Before Launch
Management & Regulatory EU Pharma Reform Changes the Investment Case Before Launch

Eight years of data protection would remain, but baseline market protection would fall from two years to one under the EU’s near-final pharmaceutical overhaul. That change puts development economics alongside faster regulatory review as a board-level concern. Companies planning European programs

Will Tougher Quality Rules Transform India's Pharma Sector?
Management & Regulatory Will Tougher Quality Rules Transform India's Pharma Sector?

The global medical supply chain relies heavily on Indian manufacturing, making any shift in domestic pharmaceutical regulations a matter of international concern for healthcare providers and patients alike. The Ministry of Health recently proposed rigorous amendments to the Drugs Rules, signaling a

How Will Lonza’s U.S. Expansion Reshape the CDMO Market?
Management & Regulatory How Will Lonza’s U.S. Expansion Reshape the CDMO Market?

The Carlsbad facility brings end-to-end viral vector solutions and aseptic fill-finish capabilities to Lonza, catering specifically to the burgeoning cell and gene therapy market. This strategic acquisition of five specialized contract development and manufacturing organization (CDMO) sites from

Will New DOL Rules Finally Bring Transparency to PBMs?
Management & Regulatory Will New DOL Rules Finally Bring Transparency to PBMs?

New federal mandates target the opaque financial arrangements between Pharmacy Benefit Managers and health plans to ensure service compensation remains reasonable under federal law. For decades, the "black box" of prescription drug pricing has frustrated employers who struggle to reconcile rising

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later